A survey of physician's attitudes regarding management of severe group A streptococcal infections

References

• Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321: 1–7
   PubMed Web of Science ®Google Scholar
• Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317: 146–9
   PubMed Web of Science ®Google Scholar
• Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269: 390–1
   PubMed Web of Science ®Google Scholar
• Kaul R, McGeer A, Low DE, Green K, Schwartz B. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiological analysis of 77 cases. Ontario Group A Streptococcal Study. Am J Med 1997; 103: 18–24
   PubMed Web of Science ®Google Scholar
• Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335: 547–54
   PubMed Web of Science ®Google Scholar
• Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial (comment). Clin Infect Dis 2003; 37: 333–40
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995–1999. Clin Infect Dis 2002; 35: 268–76
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64: 5395–8
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T-cell proliferation and cytokine production. J Immunol 1996; 156: 3057–64
   PubMed Web of Science ®Google Scholar
• Norrby-Teglund A, Low DE, McGeer A, Kotb M. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients. Adv Exp Med Biol 1997; 418: 563–6
   PubMed Web of Science ®Google Scholar
• Basma H, Norrby-Teglund A, McGeer A, Low DE, El-Ahmedy O, Dale JB, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1988; 66: 2279–83
   Web of Science ®Google Scholar
• Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude JV. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995; 21: 1469–70
   PubMed Web of Science ®Google Scholar
• Cawley MJ, Briggs M, Haith LR, Jr, Reilly KJ, Guilday RE, Braxton GR, et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 1999; 19: 1094–8
   PubMed Web of Science ®Google Scholar
• Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28: 800–7
   PubMed Web of Science ®Google Scholar
• Paul J, Seib R, Prescott T. The internet and clinical trials: background, online resources, examples and issues. J Med Internet Res 2005; 7: 5
   PubMed Web of Science ®Google Scholar
• Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. Br Med J 1995; 311: 1621–5
   PubMed Web of Science ®Google Scholar
• Tan SB, Dear KB, Bruzzi P, Machin D. Strategy for randomized clinical trials in rare cancers. Br Med J 2003; 327: 47–9
   PubMed Web of Science ®Google Scholar
• Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18: 1096–100
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhoea in a region of Quebec from 1991 to 2003:a changing pattern of disease severity. C Ma J 2004; 171: 466–72
   Google Scholar
• Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273–80
   PubMed Web of Science ®Google Scholar
• McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A. hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40: 265–72
   PubMed Web of Science ®Google Scholar
• Prevention of Invasive Group A Streptococcal Infections Workshop Participants. Prevention of invasive group A streptococcal disease among household contacts of case patients and among post partum and post-surgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002;35:950–9.
   PubMed Web of Science ®Google Scholar
• Infectious Disease Society of America website, EIN Query Results Report, http://www.idsociety.org. Cited 12 Feb 1999.
   Google Scholar
• Laupland KB, Boucher P, Rotstein C, Cook DJ, Doig CJ. Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. J Crit Care 2004; 19: 75–81
   PubMed Web of Science ®Google Scholar